Mireia Camós Guijosa
Investigador
Research group
SJD Barcelona Children's Hospital Last Publications
- Illarregi U, Bilbao-Aldaiturriaga N, Gutierrez-Camino A, Martinez de Estibariz I, Arzuaga-Mendez J, Camós-Guijosa M, Ramirez-Orellana M, Astigarraga I, Richer C, Sinnett D, Martin-Guerrero I and Lopez-Lopez E surviBALL: exploring lncRNA expression at diagnosis for 5-year EFS risk stratification in pediatric B-ALL-a proof of concept Molecular and Cellular Pediatrics . 12(1): 19-19.
- Fuentes P, García-Peydró M, Alcain J, Mosquera M, Cela C, Cifuentes C, Torrebadell-Burriel M, Isola I, Camós-Guijosa M, Ramírez M, Alarcón B and Toribio ML Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia NATURE IMMUNOLOGY . 26(10): 1712-1725.
- Falgàs A, Lázaro-Gorines R, Zanetti SR, Rubio-Pérez L, Martinez-Moreno A, Vinyoles M, Guerrero-Murillo M, Fernandez-Fuentes N, Roca-Ho H, Tirado N, Panisello C, Velasco-Hernandez T, Mayado A, Pérez-Pons A, Genesca E, Ribera JM, Ribera J, Camós-Guijosa M, Ramírez-Orellana M, Anguita E, Ballerini P, Fuster JL, Juan-Otero M, González-Navarro EAA, Locatelli F, Stam RWW, Querol S, Velasco P, Ortiz-Maldonado V, Martínez-Cibrian N, Delgado J, Orfao A, Alvarez-Vallina L, Bueno C and Menendez P A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia BLOOD . 145(22): 2599-2613.
Projects
- Project name:
- Estudio multicéntrico fase II para evaluar la eficacia y seguridad de ARI-0001 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en primera recaída o refractariedad
- Leader
- Susana Rives Solà
- Funding entities:
- Fundacio Privada Bosch y Aymerich
- Code
- PCP00480
- Starting - finishing date:
- 2026 - 2026
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Estudio multicéntrico fase 2 en pacientes pediátricos (0-18 años) con leucemia linfoblástica aguda B CD19+ en recaída o refractaria
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI21/00033
- Starting - finishing date:
- 2022 - 2026
News
-
New research facilities for studying children's cancer
New facilities have been opened for the children's oncology laboratory of the Institut de Recerca Sant Joan de Déu - SJD Barcelona Children's Hospital to celebrate 20 years of research. These laboratories are unique in their exclusive dedication to pediatric tumors and have over 50 researchers who focus on the study of more than ten developmental tumors.
More activities
-
Defensa tesi doctoral: Elena Esperanza Cebollada
Auditori Plaza, Hospital Sant Joan de Déu · Online
-
Defensa tesi doctoral: Montserrat Mesegué Medà
Auditori Plaza, Hospital Sant Joan de Déu · Online
